2,304,545 Shares in Indivior PLC $INDV Bought by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Indivior PLC (NASDAQ:INDV) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,304,545 shares of the company’s stock, valued at approximately $82,687,000. Healthcare of Ontario Pension Plan Trust Fund owned about 1.84% of Indivior as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of INDV. Goldman Sachs Group Inc. grew its position in Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after acquiring an additional 1,299,425 shares during the last quarter. Jane Street Group LLC grew its position in shares of Indivior by 2,597.9% in the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after buying an additional 958,132 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Indivior by 669.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock valued at $5,769,000 after buying an additional 340,498 shares during the last quarter. Prudential Financial Inc. bought a new stake in shares of Indivior in the 2nd quarter valued at about $207,000. Finally, Walleye Capital LLC bought a new stake in shares of Indivior in the 2nd quarter valued at about $594,000. Institutional investors own 60.33% of the company’s stock.

Insider Activity at Indivior

In related news, CFO Ryan Preblick sold 36,000 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the sale, the chief financial officer owned 284,751 shares in the company, valued at $10,735,112.70. This represents a 11.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by insiders.

Indivior Stock Performance

NASDAQ INDV opened at $38.48 on Monday. The business’s 50-day moving average price is $35.44 and its two-hundred day moving average price is $34.31. Indivior PLC has a 12 month low of $13.45 and a 12 month high of $41.00. The firm has a market capitalization of $4.69 billion, a PE ratio of 19.73 and a beta of 0.88.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The firm had revenue of $317.00 million for the quarter. As a group, analysts forecast that Indivior PLC will post 4.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on INDV. Weiss Ratings lowered Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Indivior presently has an average rating of “Buy” and a consensus price target of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.